Endoluten
Aliases: Pineal peptide bioregulator
Last verified: 2026-09-23
The short version
An oral pineal peptide complex (cytomedin class) — normalization of melatonin and neuroendocrine regulation. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian gerontology series. Status: research chemical. Supplement status.
Identity & type
- Molecular type
- bioregulator
- Origin
- An oral pineal peptide complex (cytomedin class) — normalization of melatonin and neuroendocrine regulation.
Mechanism of action
Pineal peptides + amino acids; regulation of circadian and neuroendocrine genes.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Endoluten. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–2 capsules/day orally, 10–30-day courses. A pineal bioregulator: sleep and circadian-rhythm normalization reported in the elderly; younger users rarely feel an effect.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A pineal bioregulator: sleep and circadian-rhythm normalization reported in the elderly; younger users rarely feel an effect.
Protocol — official vs community
Official / label
No approved protocol exists. Endoluten is an oral pineal peptide complex (cytomedin class) sold as a supplement; no registered drug product in any major market.
Duration: —
Supplement status only; Russian gerontology series support the circadian/neuroendocrine positioning without Western regulatory review.
Community (anecdotal)
1–2 capsules daily for 10–30 days; oral peptide uptake is unproven.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses.
Marketed as the oral counterpart to pineal bioregulators; the capsule regimen mirrors the course structure of the injectable series at unknown bioavailability.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian gerontology series.
Preclinical evidence
Russian gerontology series.
Known risks
- None reported.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.